Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Int Angiol ; 18(2): 140-4, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10424370

ABSTRACT

BACKGROUND: The white blood cell count (WCC) is known to be predictive of cardiac and cerebral vascular events. No one has yet investigated this in critical limb ischaemia (CLI). METHODS: Baseline WCC was examined in relation to lower limb amputation 6 months after a 4 week treatment period with i.v. placebo or i.v. taprostene in 366 patients with CLI. RESULTS: The WCC was related to a significant increase in amputation, relative risk 1.6 (p=0.001, 95% CI: 1.2-2.0) in CLI patients with WCC > or =9x10(9)/l vs patients with WCC <9x10(9)/l. Its association with disabling amputation persisted on logistic regression analyses which included cigarette smoking as a variable and also treatment group (p<0.001). The WCC is therefore an easily measurable prognostic variable in CLI. CONCLUSIONS: The white blood cell may promote intractable tissue ischaemia by capillary plugging and/or release of toxic chemicals and may have distinct effects on tissue viability.


Subject(s)
Ischemia/surgery , Leg/blood supply , Neutrophils/cytology , Amputation, Surgical , Cardiovascular Agents/therapeutic use , Double-Blind Method , Epoprostenol/analogs & derivatives , Epoprostenol/therapeutic use , Female , Humans , Leukocyte Count/drug effects , Logistic Models , Male , Placebos , Single-Blind Method , Smoking
2.
Arzneimittelforschung ; 41(5): 489-93, 1991 May.
Article in German | MEDLINE | ID: mdl-1680325

ABSTRACT

Duration of Action of Betaadrenergic Blockers Determined with Holter-ECG in Healthy Volunteers In phase I, the duration of action of betaadrenergic blockers is usually determined from the reduction of exercise induced tachycardia. In this randomized placebocontrolled doubleblind trial, however, ambulatory 24-h heart rate monitoring was used in 12 healthy volunteers to evaluate the duration of action of the new cardioselective and vasodilating betaadrenergic blocker ridazolol (CAS413). After the control periods as well as after prospectively defined hours the following mean values of heart rate were obtained: Ridazolol: Control 65.2, 12 h 69.6, 16 h 64.9, 24 h 74.0 beasts/min, placebo: Control 64.8, 12 h 78.5, 16 h 69.7, 24 h 73.5 beats/min. Differences after 12 h were statistically significant and would have been significant after 16 h with more volunteers. Additional explorative analysis with adjustment of significance levels for multiple analysis resulted in significant effects from 2 to 14 h. It was not useful, however, to calculate the time of maximal and half-maximal effects because of the large individual variation. Holter-monitoring of spontaneous heart rate in volunteers provides a rapid orientation on the duration of action of betaadrenergic blockers. The method allows to fix prospectively reasonable times of evaluation in efficacy trials in patients with coronary artery disease.


Subject(s)
Adrenergic beta-Antagonists/pharmacology , Electrocardiography, Ambulatory , Adult , Double-Blind Method , Heart/drug effects , Heart Rate/drug effects , Humans , Male , Middle Aged , Pyridazines/pharmacology , Time Factors , Vasodilation/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...